Urogen Pharma Ltd
URGN
View Detailed Chart
23.760USD
+0.360+1.54%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.54%
5 Days
+5.04%
1 Month
-11.77%
6 Months
+72.30%
Year to Date
+123.10%
1 Year
+119.59%
View Detailed Chart
TradingKey Stock Score of Urogen Pharma Ltd
Currency: USD Updated: 2025-12-24Key Insights
Urogen Pharma Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 43/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.25.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Urogen Pharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
35.250
Target Price
+52.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Urogen Pharma Ltd Highlights
StrengthsRisks
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.46% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.40M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 90.40M.
Undervalued
The company’s latest PE is -7.29, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.66M shares, decreasing 12.60% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 303.79K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.24.
Urogen Pharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Urogen Pharma Ltd Info
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Ticker SymbolURGN
CompanyUrogen Pharma Ltd
CEOBarrett (Elizabeth A)
Websitehttps://www.urogen.com/
FAQs
What is the current price of Urogen Pharma Ltd (URGN)?
The current price of Urogen Pharma Ltd (URGN) is 23.760.
What is the symbol of Urogen Pharma Ltd?
The ticker symbol of Urogen Pharma Ltd is URGN.
What is the 52-week high of Urogen Pharma Ltd?
The 52-week high of Urogen Pharma Ltd is 30.000.
What is the 52-week low of Urogen Pharma Ltd?
The 52-week low of Urogen Pharma Ltd is 3.420.
What is the market capitalization of Urogen Pharma Ltd?
The market capitalization of Urogen Pharma Ltd is 1.11B.
What is the net income of Urogen Pharma Ltd?
The net income of Urogen Pharma Ltd is -126.87M.
Is Urogen Pharma Ltd (URGN) currently rated as Buy, Hold, or Sell?
According to analysts, Urogen Pharma Ltd (URGN) has an overall rating of Buy, with a price target of 35.250.
What is the Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN)?
The Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN) is -3.258.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
